Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Reference #1 Abstract Supplementary Materials REFERENCES AND NOTES eLetters (0) Information & Authors Metrics & Citations Check Access References Figures Tables Media Share This article has 0 eLetter . Abstract Expanded CAG/CTG repeats cause more than 15 different diseases that all remain without a disease-modifying treatment. Because repeat length accounts for most of the variation in disease severity, contracting CAG/CTG repeats presents an attractive therapeutic avenue.
A patient with refractory CM showed the greatest improvement with a dual therapy of Botox and a CGRP receptor monoclonal antagonist antibody. By Houssein Salem-Abdou, MD, PhD, Pierre Naud, MD and Jack Puymirat, MD, PhD Pages 45-47 The prevalence of chronic migraine (CM) is estimated to be about 1.4% to 2.2% worldwide.1 Several preventive treatments are available for patients afflicted with this condition, including sodium valproate, topiramate, and propranolol.
Secreted protein, acidic and rich in cysteine (SPARC) is differentially associated with cell proliferation and extracellular matrix (ECM) assembly. We show here the effect of exogenous SPARC inhibition/induction on ECM and mitochondrial proteins expression and on the differentiation of C2C12 cells. The cells were cultured in growth medium (GM) supplemented with different experimental conditions.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
